faldaprevir

Faldaprevir is a potent, orally administered small molecule inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It was developed by Boehringer-Ingelheim for the treatment of chronic hepatitis C infection. Faldaprevir demonstrated high in vitro activity against HCV genotypes 1a and 1b and was evaluated in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antivirals such as deleobuvir. The drug reached phase 3 clinical trials but development was discontinued in 2014 due to the emergence of more effective HCV therapies. Its mechanism of action involves inhibition of the viral NS3/4A protease, an enzyme essential for viral replication[2][3][5].

Other names

faldaprevirBI 201335BI201335BI-201335